New Two-Drug attack on advanced liver cancer enters final testing phase
NCT ID NCT04523493
Summary
This study is testing if adding a new immunotherapy drug (toripalimab) to an existing cancer drug (lenvatinib) works better than lenvatinib alone for people with advanced liver cancer. It is a large, late-stage trial involving 530 participants who have not had prior systemic treatment. The main goal is to see if the combination helps patients live longer and controls the cancer better, while closely monitoring side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O.U. Citta della Salute e della Scienza di Torino
Tortona, Italy
-
AOUI Verona - Policlinico "G.B. Rossi" di Borgo Roma
Verona, 37134, Italy
-
Azienda Ospedaliero Universitaria Pisana
Pisa, 56126, Italy
-
Centrum Medyczne Pratia Poznań
Skórzewo, 60-185, Poland
-
Communal Enterprise Volyn Regional Clinical Hospital of Volyn Regional Council
Lutsk, 43018, Ukraine
-
Communal Non-Profit Institution of Kharkiv Regional Council Regional Clinical Specialized Dispensary of Radiation Protection of Population
Kharkiv, 61166, Ukraine
-
Communal Non-commercial Enterprise City Clinical Hospital #4 of Dnipro City Council, Department of Chemotherapy
Dnipro, 49102, Ukraine
-
Communal Non-commercial Enterprise Odesa Regional Clinical Hospital of Odesa Regional Council, Department of General Surgery
Odesa, 65025, Ukraine
-
Communal Non-commercial Enterprise Zaporizhzhia Regional Antitumor Center of Zaporizhzhia Regional Council
Zaporizhzhia, 69040, Ukraine
-
Communal Non-commercial Enterprise of Sumy Regional Council, Sumy Regional Clinical Oncological Dispensar
Sumy, 40022, Ukraine
-
Communal Non-profit Enterprise "Regional Center of Oncology", Department of Abdominal Organs Oncosurgery
Kharkiv, 61070, Ukraine
-
Copernicus Podmiot Leczniczy sp. z o.o., Wojewodzkie Centrum Onkologii, Oddzial Onkologii Klinicznej/Chemioterapii
Gdansk, 80-219, Poland
-
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico,Oncologia Medica
Milan, 20122, Italy
-
ID Clinic
Mysłowice, 41-400, Poland
-
IRCCS Fondazione Giovanni Pascale, Istituto Nazionale Dei Tumori
Naples, 80131, Italy
-
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Klinika Onkologii i Radioterapii
Warsaw, 02-034, Poland
-
National Cancer Centre Singapore
Singapore, 168583, Singapore
-
PRATIA MCM Kraków, ul. Pana Tadeusza 2,
Krakow, 30-727, Poland
-
Qinhuai Medical Area, General Hospital of PLA Eastern Theater Command
Nanjing, Jiangsu, 21000, China
-
State Inst. O.O.Shalimov Nat. scientific certer of Surgery and Transplantology of Nat. Academy of Med.Sciences of Ukraine, Dep.of Oncology
Kyiv, 03126, Ukraine
-
Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie, Oddzial Dzienny Chemioterapii
Koszalin, 75-581, Poland
-
Wielkopolskie Centrum Onkologii, Oddział Onkologii Klinicznej i Immunoonkologii z Pododdziałem Dziennym i Izbą Przyjęć
Poznan, 61-866, Poland
Conditions
Explore the condition pages connected to this study.